Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis

被引:0
|
作者
Heiko Schotte
Hartmut Schmidt
Markus Gaubitz
Susanne Drynda
Jörn Kekow
Peter Willeke
Bernhard Schlüter
机构
[1] Franziskus-Hospital Harderberg,Niels
[2] Universitätsklinikum Münster,Stensen
[3] Akademie für Manuelle Medizin,Kliniken
[4] Universität Magdeburg,Centrum für Laboratoriumsmedizin
[5] Universitätsklinikum Münster,Rheumatologie
来源
Clinical Rheumatology | 2015年 / 34卷
关键词
Arthritis; Etanercept; Genotypes; IL-6 promoter; Rheumatoid;
D O I
暂无
中图分类号
学科分类号
摘要
Indices prognosticating anti-tumor necrosis factor (TNF) response in patients with rheumatoid arthritis are a matter of interest. Differential outcome under anti-TNF and anti-interleukin-6 (IL-6) therapy raises the question whether genetic polymorphisms that have previously been linked to IL-6 production are associated with response to anti-TNF therapy. Fifty (50) rheumatoid arthritis (RA) patients were treated with etanercept (median 36 weeks, range 4–52). In terms of the EULAR response criteria, 25 patients responded well, 17 patients moderately and 8 patients not. By direct sequencing, the patients and 91 matched healthy controls were genotyped for the IL-6 promoter SNPs -597G > A (rs1800797), -572G > C (rs1800796) and -174G > C (rs1800795) and for an AnTn microsatellite tract at -373. Alleles and haplotypes were tested for association with disease susceptibility and therapy response. No significant difference was seen in the genotype distribution between patients and healthy controls. Confirming the results of previous studies, we observed a trend of -174G being more frequent in patients with a good or moderate therapy response. Beyond that, carriage of the A9T11 microsatellite allele within the -174G haplotype was associated most closely with a favourable response (relative risk 1.31; 95 % confidence interval 1.02–1.68). A subtle analysis of the IL-6 promoter giving respect to its complex haplotypic structure results in more precise information as to the association of genotypes with the long-term etanercept response. Despite a conclusive hypothesis that a genetically determined IL-6-dominated RA responds less well to anti-TNF, more work has to be done to provide us with reliable information regarding the functional aspects of these genetic polymorphisms.
引用
收藏
页码:2021 / 2028
页数:7
相关论文
共 50 条
  • [1] Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis
    Schotte, Heiko
    Schmidt, Hartmut
    Gaubitz, Markus
    Drynda, Susanne
    Kekow, Joern
    Willeke, Peter
    Schlueter, Bernhard
    [J]. CLINICAL RHEUMATOLOGY, 2015, 34 (12) : 2021 - 2028
  • [2] -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
    Ivan Jančić
    Nevena Arsenović-Ranin
    Mirjana Šefik-Bukilica
    Sladjana Živojinović
    Nemanja Damjanov
    Vesna Spasovski
    Sanja Srzentić
    Biljana Stanković
    Sonja Pavlović
    [J]. Rheumatology International, 2013, 33 : 1481 - 1486
  • [3] -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
    Jancic, Ivan
    Arsenovic-Ranin, Nevena
    Sefik-Bukilica, Mirjana
    Zivojinovic, Sladjana
    Damjanov, Nemanja
    Spasovski, Vesna
    Srzentic, Sanja
    Stankovic, Biljana
    Pavlovic, Sonja
    [J]. RHEUMATOLOGY INTERNATIONAL, 2013, 33 (06) : 1481 - 1486
  • [4] Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses
    Rivera-Chavez, FA
    Peters-Hybki, DL
    Barber, RC
    O'Keefe, GE
    [J]. SHOCK, 2003, 20 (03): : 218 - 223
  • [5] Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis
    Schotte, H
    Schlüter, B
    Drynda, S
    Willeke, P
    Tidow, N
    Assmann, G
    Domschke, W
    Kekow, J
    Gaubitz, M
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) : 575 - 581
  • [6] Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis
    Shi, Rui
    Chen, Muzhi
    Litifu, Bahaerguli
    Zhaorigetu
    [J]. MODERN RHEUMATOLOGY, 2018, 28 (01) : 126 - 132
  • [7] Interleukin-10 promoter polymorphisms are associated with response to longterm treatment with etanercept in rheumatoid arthritis
    Schotte, H
    Schlüter, B
    Willeke, P
    Schorat, MA
    Tidow, N
    Domschke, W
    Gaubitz, M
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 85 - 86
  • [8] Interleukin-6 gene-174 promoter polymorphism is associated with endothelial dysfunction in patients with rheumatoid arthritis
    Gonzalez Juanatey, C.
    Gonzalez-Gay, M. A.
    Palomino-Morales, R.
    Testa, A.
    Vazquez, T.
    Miranda, J. A.
    Regueiro, M.
    Martin, J.
    Llorca, J.
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 : 901 - 901
  • [9] Interleukin-6 in Rheumatoid Arthritis
    Pandolfi, Franco
    Franza, Laura
    Carusi, Valentina
    Altamura, Simona
    Andriollo, Gloria
    Nucera, Eleonora
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15)
  • [10] Interleukin-6 Gene Promoter Methylation in Rheumatoid Arthritis and Chronic Periodontitis
    Ishida, Kohei
    Kobayashi, Tetsuo
    Ito, Satoshi
    Komatsu, Yasutaka
    Yokoyama, Tomoko
    Okada, Moe
    Abe, Asami
    Murasawa, Akira
    Yoshie, Hiromasa
    [J]. JOURNAL OF PERIODONTOLOGY, 2012, 83 (07) : 917 - 925